Welcome to our dedicated page for Biocardia news (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on Biocardia stock.
BioCardia, Inc. (Nasdaq: BCDA) is a clinical-stage leader developing cellular therapies for cardiovascular and pulmonary diseases. This news hub provides investors and medical professionals with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access verified press releases and analysis covering the company’s proprietary CardiAMP® cell therapy platform, Morph® delivery systems, and strategic partnerships. Track progress across key areas including FDA designations, randomized controlled trials, and intellectual property advancements.
Our curated news collection enables informed decision-making with updates on ischemic heart failure therapies, financial disclosures, and scientific breakthroughs. Content is organized for quick scanning while maintaining technical accuracy for expert audiences.
Bookmark this page for consolidated access to BioCardia’s latest developments in regenerative medicine, including updates on the CardiALLO allogeneic cell therapy platform and Helix™ biotherapeutic delivery technology.
BioCardia (Nasdaq: BCDA) reported its Q1 2024 financial results and business highlights. Key developments include a 37% relative risk reduction in mortality for patients with ischemic heart failure using CardiAMP therapy, and a confirmatory pivotal trial with CMS reimbursement. CardiAMP therapy for refractory angina improved exercise tolerance and reduced chest pain. CardiALLO therapy showed no adverse events in the low-dose cohort. The company reported Q1 revenues of $55,000, a net loss of $2.3 million, and a $1.5 million operational cash burn. Significant milestones for 2024 include advancing pivotal trials, FDA submissions, and biotherapeutic delivery partnerships.
BioCardia, Inc. will host a conference call on May 14, 2024, to discuss its financial results for the first quarter of 2024 and provide a corporate update. The company specializes in developing therapeutics for cardiovascular and pulmonary diseases.
BioCardia, Inc., a developer of therapeutics for cardiovascular and pulmonary diseases, announced positive results from the CardiAMP Cell Therapy Trial in Chronic Myocardial Ischemia. Patients showed increased exercise tolerance and reduced angina episodes, outperforming FDA-approved therapies. The webcast can be accessed for further details. The results support BioCardia's efforts in transforming angina treatment through cost-effective cell-based therapy.
FAQ
What is the current stock price of Biocardia (BCDA)?
What is the market cap of Biocardia (BCDA)?
